NanoVibronix Announces Webinar Series to Promote UroShield
July 12 2022 - 8:30AM
Business Wire
Educational Marketing Aimed at Expanding
Product Awareness in Australia and New Zealand
NanoVibronix, Inc., (NASDAQ: NAOV), a medical device
company utilizing the Company's proprietary and patented low
intensity surface acoustic wave (SAW) technology, today announced
its Australian distributor, DukeHill HC, is launching a series of
educational webinars to present the Company’s UroShield technology
to clinicians. The series, which will feature clinicians and
patients’ experiences, seeks to inform clinicians about the use,
benefits and outcomes achieved when using the Company’s device.
“This webinar series is designed to increase awareness of
UroShield and drive increased sales through our Australian
distribution partner, DukeHill HC,” stated Brian Murphy, CEO of
NanoVibronix, Inc. “Over the course of three, one-hour webinars,
our technology will be introduced to hundreds of clinicians.
Clinicians can gain valuable insight into our UroShield device by
learning how it is used and the patients who can benefit from its
use. Participants will have an opportunity to ask questions, and
each webinar will feature case studies and testimonials from
patients who have been treated with the device.”
Murphy added, “Subsequent to the webinar series, DukeHill will
be launching a social media campaign to supplement the marketing
efforts and further increase product and brand awareness.”
The first webinar is scheduled for July 21, 2022. Subsequent
sessions are scheduled for August 4 and 18, 2022. For additional
information, please visit DukeHill Webinar Promo - YouTube.
The webinars will be recorded and made available for replay on
the Company’s website at: https://www.nanovibronix.com.
About DukeHill HC
DukeHill HC is a leader in advancing clinical education and has
a high level of clinical and technical expertise with a strong
focus on meeting the changing healthcare requirements in Australia.
DukeHill HC’s purpose is to address the needs of healthcare
professionals with the supply of quality, cost effective, minimally
invasive, and consumable devices which will enable clinicians to
obtain best practice outcomes for their patients.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The devices can be
administered at home without the assistance of medical
professionals. The Company’s primary products include PainShield®
and UroShield®, which are portable devices suitable for
administration at home without assistance of medical professionals.
Additional information about NanoVibronix is available at:
www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) the geographic, social and
economic impact of COVID-19 on the Company’s ability to conduct its
business and raise capital in the future when needed, (ii) market
acceptance of our existing and new products or lengthy product
delays in key markets; (iii) negative or unreliable clinical trial
results; (iv) inability to secure regulatory approvals for the sale
of our products; (v) intense competition in the medical device
industry from much larger, multinational companies; (vi) product
liability claims; (vii) product malfunctions; (viii) our limited
manufacturing capabilities and reliance on subcontractor
assistance; (ix) insufficient or inadequate reimbursements by
governmental and/or other third party payers for our products; (x)
our ability to successfully obtain and maintain intellectual
property protection covering our products; (xi) legislative or
regulatory reform impacting the healthcare system in the U.S. or in
foreign jurisdictions; (xii) our reliance on single suppliers for
certain product components, (xiii) the need to raise additional
capital to meet our future business requirements and obligations,
given the fact that such capital may not be available, or may be
costly, dilutive or difficult to obtain; (xiv) our conducting
business in foreign jurisdictions exposing us to additional
challenges, such as foreign currency exchange rate fluctuations,
logistical and communications challenges, the burden and cost of
compliance with foreign laws, and political and/or economic
instabilities in specific jurisdictions; and (xv) market and other
conditions. More detailed information about the Company and the
risk factors that may affect the realization of forward-looking
statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at: http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events, or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220712005143/en/
Investor Contacts:
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Apr 2023 to Apr 2024